Wells Fargo Maintains an 'Outperform' on MannKind (MNKD); Inspection Extends FDA Review of Afrezza, No Other Delays
Tweet Send to a Friend
Wells Fargo maintains an Outperform rating on MannKind (Nasdaq: MNKD), Valuation range $11-$13.
Wells analyst says, "FDA extends review of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells analyst says, "FDA extends review of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
